

## In 2023, Holodiag strengthens its analytical capabilities

VAL-DE-REUIL, 8th of September, 2023 - In order to reinforce our analytical capabilities, a second XRPD and a second DVS joined our laboratories in 2023.

X-Ray Powder Diffraction is currently the main technique to characterize pharmaceutical solids (raw material or formulation control, crystallinity or amorphous content measurements, desolvation or polymorphic transition monitoring). Demand is constantly growing.

On the other hand, Dynamic Vapor Sorption allows to monitor sample mass variation vs. Relative Humidity (RH), enabling accurate depiction of hydrate stoichiometry and stability, hygroscopicity and drying conditions.

Moreover, new laminar flow hoods have been installed and qualified in order to enable handling of toxic samples for all our analyses (OEL: 50 ng/m<sup>3</sup>).

Finally, two more PhDs and one more research assistant joined our scientific team within a year.

About the company: Holodiag is a Contract Research Organization dedicated to solid state, polymorphism and crystallization processes of small molecules. Since 2006, we offer CMC services to pharmaceutical, specialty chemicals, animal health, advanced-materials and agro-sciences industries. Headquartered in Normandy-France, we support our customers with the development of the right solid phases throughout the pharmaceutical development process, from pre-development to production.

[Learn more about Holodiag's services for pharma development](https://www.holodiag.com)

<https://www.holodiag.com>

###

Léa Tézé-Copreaux 

Business Developer

+33 (0) 628 767 205

lea.teze-copreaux@holodiag.com

Pierric Marchand, Phd 

Founder and CEO

+33 (0) 232 405 826

pierric.marchand@holodiag.com